ANTABIO

The U.S. drug discovery outsourcing market was valued at USD 1.85 billion in 2023, expected to reach USD 3.44 billion by 2033, driven by public-private partnerships, disease prevalence, and AI advancements. Key segments include lead identification & candidate optimization, respiratory system, and small molecules.

Antabio completed Phase 1 trial for MEM-ANT3310, a broad-spectrum antibacterial combination designed to combat antimicrobial resistance in severe hospital infections. The trial showed good tolerability and no serious adverse events, supporting further patient studies.